Treatment options for patients with WM in the third‑line setting

The main topics discussed included: 

Buske begins by discussing the available options for treating patients with WM in the third-line setting. The panel notes that approved treatments for the third-line are very limited and treatment approaches include either repeating initial therapies or referring patients to clinical trials. The panel discusses ongoing clinical trials, highlighting the latest data for Bruton’s tyrosine kinase inhibitors, BCL-2 inhibitors, novel nuclear medicines such as iopofosine, and combination therapies for the treatment of WM. The panel also discusses the possible use of immunotherapies, including bispecific antibodies and CAR T-cell therapies for the treatment of patients with WM, and emphasize the importance of gaining data specifically in WM. Finally, Castillo discusses the positioning of autologous transplants in current clinical practice and whether strategies to retreat patients with prior lines of therapies are still warranted given the number of emerging therapies for WM. 

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom's macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.

This initiative is funded by Cellectar Biosciences. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.